AKYA Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -38.41% compared to Akoya Biosciences's net margin of -728.57%. Akoya Biosciences's return on equity of -212.99% beat Bionano Genomics's return on equity of -158.95%.

Akoya Biosciences has a consensus price target of $2.99, signalling upside risk potential of 171.82%. On the other hand Bionano Genomics has an analysts' consensus of $7.00 which suggests that it could grow by 75%. Given that Akoya Biosciences has higher upside potential than Bionano Genomics, analysts believe Akoya Biosciences is more attractive than Bionano Genomics.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.086, suggesting its more volatile than the S&P 500 by 108.641%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $21.3M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Akoya Biosciences's net income of -$8.2M is higher than Bionano Genomics's net income of -$44.2M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.67x versus 0.10x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -38.41% compared to Akoya Biosciences's net margin of 1.4%. Akoya Biosciences's return on equity of -212.99% beat Bruker's return on equity of 6.78%.

Akoya Biosciences has a consensus price target of $2.99, signalling upside risk potential of 171.82%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 67.12%. Given that Akoya Biosciences has higher upside potential than Bruker, analysts believe Akoya Biosciences is more attractive than Bruker.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.56% to investors and pays a quarterly dividend of $0.05 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Akoya Biosciences quarterly revenues are $21.3M, which are smaller than Bruker quarterly revenues of $979.6M. Akoya Biosciences's net income of -$8.2M is lower than Bruker's net income of $13.7M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bruker's PE ratio is 47.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.67x versus 1.60x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -38.41% compared to Akoya Biosciences's net margin of 0.07%. Akoya Biosciences's return on equity of -212.99% beat Harvard Bioscience's return on equity of -18.36%.

Akoya Biosciences has a consensus price target of $2.99, signalling upside risk potential of 171.82%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1135.59%. Given that Harvard Bioscience has higher upside potential than Akoya Biosciences, analysts believe Harvard Bioscience is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.794%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $21.3M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Akoya Biosciences's net income of -$8.2M is lower than Harvard Bioscience's net income of $18K. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.67x versus 0.17x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -38.41% compared to Akoya Biosciences's net margin of -34.09%. Akoya Biosciences's return on equity of -212.99% beat Quanterix's return on equity of -11.35%.

Akoya Biosciences has a consensus price target of $2.99, signalling upside risk potential of 171.82%. On the other hand Quanterix has an analysts' consensus of $13.13 which suggests that it could grow by 168.41%. Given that Akoya Biosciences has higher upside potential than Quanterix, analysts believe Akoya Biosciences is more attractive than Quanterix.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.351, suggesting its more volatile than the S&P 500 by 35.098%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $21.3M, which are smaller than Quanterix quarterly revenues of $34.1M. Akoya Biosciences's net income of -$8.2M is higher than Quanterix's net income of -$11.6M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.67x versus 1.39x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.